April 28th 2025
Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.
A Watershed on Transparency and International Collaboration in Drug Pricing?
May 30th 2019The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact on market access around the world, writes Neil Grubert.
Precision Financing of Durable, Potentially Curative Therapies
January 27th 2019While gene therapies and cellular treatments are a boon for patients, they can be a financial bane for payers. Jane Barlow, Russell Teagarden, and Mark Trusheim outline alternative financing approaches, customizable for each payer’s needs and for each therapy’s characteristics.
8 Tipping Points: Pharm Exec’s 2019 Industry Forecast
January 23rd 2019Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.